Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Nova Eye Medical's Enterprise Value is $31.81 Mil.
Nova Eye Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.20 Mil. Therefore, Nova Eye Medical's EV-to-OCF for today is -9.94.
The historical rank and industry rank for Nova Eye Medical's EV-to-OCF or its related term are showing as below:
ELXMF'
s EV-to-OCF Range Over the Past 10 Years
Min: -42.35 Med: -4.9 Max: 187.93
Current: -9.25
During the past 13 years, the highest EV-to-OCF of Nova Eye Medical was 187.93. The lowest was -42.35. And the median was -4.90.
ELXMF's EV-to-OCF is ranked better than 79.6% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.94
vs ELXMF: -9.25
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nova Eye Medical (OTCPK:ELXMF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nova Eye Medical's PE Ratio (TTM) for today is calculated as:
Nova Eye Medical's share price for today is $0.01431.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nova Eye Medical EV-to-OCF Related Terms
Nova Eye Medical EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's EV-to-OCF falls into.
Nova Eye Medical's current Enterprise Value is $31.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (ELXMF) has a EV-to-OCF of -9.94 as of Aug. 13, 2026. According to the industry distribution chart, Nova Eye Medical ranks #174 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 20.4%.
Is Nova Eye Medical's EV-to-OCF too high?
Nova Eye Medical's current EV-to-OCF is -9.94. Based on the distribution chart, Nova Eye Medical ranks #174 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nova Eye Medical has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #174 out of 853 companies for EV-to-OCF. This places Nova Eye Medical in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.94, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current EV-to-OCF is -9.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current EV-to-OCF of -9.94. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current EV-to-OCF is -9.94. Nova Eye Medical's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current EV-to-OCF is -9.94 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
EV-to-OCF: -9.94
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
42GF Score
Get the complete analysis for ELXMF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
